foxo4-dri vs gdf-11

foxo4-dri vs gdf-11 Structural basis for potency differences between GDF8 and GDF11 | BMC Biology The disordered p53 transactivation domain

Name: foxo4-dri vs gdf-11 Structural basis for potency differences between GDF8 and GDF11 | BMC Biology The disordered p53 transactivation domain
Brand: l2q2.es
SKU: 78791854346
Price: 23.93 USD
Availability: InStock
Rating: 4.8559 (13 reviews)

The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging: Cell FOXO4 DRI improves spermatogenesis in aged mice through reducing senescence associated secretory phenotype secretion from Leydig cells ScienceDirect Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells eBioMedicine

SKU: 78791854346 · From l2q2.es

4.9

USD23.93 USD73.93

Pay in 4 interest-free payments of $5.98 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

Description

References and Storage Sources Peptide stability guidance is consistent on the main principle: dry peptide powder is more stable than peptide solution, and reconstituted peptides require shorter, colder, cleaner handling